|
Apr 9
|
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
|
|
Mar 27
|
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
|
|
Mar 20
|
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 17
|
Estimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT)
|
|
Mar 15
|
Vaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call Transcript
|
|
Mar 15
|
Q4 2023 Vaxart Inc Earnings Call
|
|
Mar 14
|
Vaxart Inc (VXRT) Reports Full Year 2023 Financial Results
|
|
Mar 14
|
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
|
|
Mar 7
|
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
|
|
Mar 6
|
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
|
|
Feb 26
|
VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy?
|
|
Feb 5
|
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
|
|
Jan 16
|
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
|
|
Jan 16
|
Vaxart, Inc. Announces Management Change
|
|
Dec 21
|
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
|
|
Nov 7
|
Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely
|
|
Nov 3
|
Vaxart, Inc. (NASDAQ:VXRT) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
Vaxart Inc (VXRT) Reports Q3 2023 Financial Results and Business Updates
|
|
Nov 2
|
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
|
|
Nov 2
|
Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
|